Sinaptica Therapeutics
5 known investors
Sinaptica develops a noninvasive, personalized closed-loop rTMS-EEG neuromodulation therapy for Alzheimer's disease that stimulates the precuneus and Default Mode Network to slow disease progression. The therapy targets cognition, function, and behavior and is calibrated per patient using MRI and TMS-evoked potential data.
BiotechDigital HealthMedical Devices
Investors · 5
Frequently asked questions
- What does Sinaptica Therapeutics do?
- Sinaptica develops a noninvasive, personalized closed-loop rTMS-EEG neuromodulation therapy for Alzheimer's disease that stimulates the precuneus and Default Mode Network to slow disease progression. The therapy targets cognition, function, and behavior and is calibrated per patient using MRI and TMS-evoked potential data.
- Who are Sinaptica Therapeutics's investors?
- Sinaptica Therapeutics's investors include Bootstrap Venture Partners, Healthtech Capital, NW Angel, Sony Ventures Corporation, Time Zero Capital.